688177 Bio-Thera Solutions,
- 21.64
- -0.56-2.52%
Bio-Thera Solutions, News
Bio-thera solutions (688177.SH): The company's bevacizumab has not yet started selling in the European Union and the USA.
Ge Longhui 21st November丨Bio-Thera Solutions (688177.SH) stated on the interactive platform that the company's Bevacizumab monoclonal antibody has not yet started sales in the European Union and USA; TOFIDENCE (Tuzumab monoclonal antibody) started sales in the USA in May this year, and the listing time in the European Union is yet to be determined. Other overseas markets have not yet been approved for listing, and the company will actively follow up to promote the relevant processes. The company recognizes revenue in accordance with accounting standards, and part of the 10 million milestone from Hikma is included in the revenue. For specific information on the breakdown of revenue, please refer to the company's disclosure in the "Bio-Thera Solutions 2024 Interim Report" in statutory media.
Bio-Thera Solutions Receives $10 Million Payment Related to Licensing Deal
bio-thera solutions has achieved some results in overseas authorization, with 10 million USD entering the account, which may alleviate cash / money market tightness.
After authorizing the injection of BAT2206 (Keytruda monoclonal antibody) to Jirui Medicine for one month, bio-thera solutions received a payment of 10 million US dollars from the other party, providing supplementary cash flow for rapid consumption; Due to intense competition in the domestic market and vast market space overseas, apart from bio-thera solutions, many pharmaceutical enterprises have completed overseas expansion this year.
Bio-Thera Solutions (688177.SH): received a one-time payment of $10 million from Jirui Pharmaceuticals.
Bio-Thera Solutions (688177.SH) announced on November 13 that on October 8, 2024, Bio-Thera signed an authorization, production, supply, and commercialization agreement with Gedeon Richter Plc. (referred to as "Gedeon Richter") for BAT2206 (ustekinumab) injection. The exclusive commercialization rights for the company's BAT2206 (ustekinumab) injection in the European Union, United Kingdom, Swiss Franc, Australia, and some other European countries' markets were granted to Gedeon Richter on a compensated license. The total amount of the down payment and milestone payment is up to 0.11 billion US dollars.
Bio-Thera Solutions, Ltd.'s (SHSE:688177) Last Week's 8.7% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Biotech 2024 Third Quarter Report
bio-thera solutions (688177.SH) releases performance for the first three quarters, with a net loss of 0.365 billion yuan
Bio-Thera Solutions (688177.SH) released the report for the first three quarters of 2024. During the reporting period, the company achieved revenue of 5...
Bio-Thera Solutions (688177.SH): a net loss of 0.365 billion yuan in the first three quarters.
GeLongHui October 29 | Bio-Thera Solutions (688177.SH) announced that in the first three quarters of 2024, revenue reached 0.581 billion yuan, a year-on-year increase of 26.11%; net income attributable to shareholders of the listed company was -0.365 billion yuan, with a basic earnings per share of -0.88 yuan.
Bocom Intl: Guangzhou launches first batch of innovative drugs and medical devices catalog, focusing on innovation and consumer properties as symbols.
Following the introduction of policies encouraging the innovation of pharmaceuticals, the latest innovative drug and medical device product catalog released by Guangzhou will further provide full-chain, all-field support to the high-quality development of the biomedical industry.
Star Evening News | Minmetals New Energy, Bio-Thera Solutions, and 6 other companies announced their shareholding reduction plans. Vertical and horizontal shares receive an administrative supervision decision letter from Sichuan Securities Regulatory Bure
1. Guangdong may introduce demonstration clauses for technology insurance such as biomedical and integrated circuits; 2. Shenzhen: Accelerating the establishment of a multi-billion-dollar Shenzhen semiconductor and integrated circuit industry investment fund; 3. The Shanghai Stock Exchange terminates the listing and issuance review of Feixiang Technology on the Star Market.
Bio-Thera Solutions Enters Up to $110 Million Licensing Deal With Gedeon Richter
Express News | Hungary's Richter Says Bio-Thera Will Receive an Upfront Payyment of 8.5 Million USD -Statement
Express News | Hungary's Richter Says Bat2206 Is a Biosimilar Candidate to Stelara (Ustekinumab) -Statement
Express News | China's Bio-Thera and Hungary's Richter Execute Exclusive Commercialization Agreement for Bat2206 for EU Countries, UK, Switzerland and Other Countries
Bio-Thera Solutions (688177.SH) has granted the commercialization rights of BAT2206 injection to Girui Pharmaceuticals in exclusive areas on a paid licensing basis.
bio-thera solutions (688177.SH) announced that the company has signed a strategic collaboration agreement with Gedeon Richter Plc....
Bio-Thera Solutions, Ltd. (SHSE:688177) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Bio-Thera Solutions (688177.SH): Therabio has not reduced its shareholding upon the expiration of the Fanwan Lake reduction plan.
Bio-Thera Solutions (688177.SH) announced that the company received a notice from shareholder Thera on September 24, 2024.
Would Bio-Thera Solutions (SHSE:688177) Be Better Off With Less Debt?
Bio-Thera Solutions, Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE, An Approved Biosimilar Referencing Tocilizumab In Arthritis Research & Therapy
Bio-Thera Solutions 2024 Semi-Annual Report
No Data
